



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

| APPL NO. | FILING OR 371 (c) DATE | ART UNIT | FIL FEE REC'D | ATTY. DOCKET NO | DRAWINGS | TOT CLMS | IND CLMS |
|------------|---------------------------|----------|---------------|-----------------|----------|----------|----------|
| 10/659,747 | 09/11/2003 | 1616 | 0.00 | 26682 | 7 | 93 | 5 |

G.E. EHRLICH (1995) LTD.
c/o ANTHONY CASTORINA
SUITE 207
2001 JEFFERSON DAVIS HIGHWAY
ARLINGTON, VA 22202

CONFIRMATION NO. 3467

FILING RECEIPT



OC000000012568197

Date Mailed: 05/07/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Alexander Levitzki, Jerusalem, ISRAEL;
Eyal Mishani, Mevasseret Zion, ISRAEL;
Giuseppina Ortu, Jerusalem, ISRAEL;
Iris Ben-David, Ashdod, ISRAEL;
Yulia Rozen, Jerusalem, ISRAEL;

Domestic Priority data as claimed by applicant

This application is a CIP of PCT/IL02/00199 03/12/2002

Foreign Applications

If Required, Foreign Filing License Granted: 05/07/2004

Projected Publication Date: To Be Determined - pending completion of Missing Parts

Non-Publication Request: No

Early Publication Request: No

** SMALL ENTITY **

Title

Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy

Preliminary Class

424

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

APPLICATION FOR PATENT

Inventors: Alexander Levitzki, Eyal Mishani, Giuseppina Ortu, Iris Ben
David and Yulia Rozen

Title: RADIOLABELED IRREVERSIBLE INHIBITORS OF
EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE
KINASE AND THEIR USE IN RADIOIMAGING AND
RADIOTHERAPY

This is a continuation-in-part of PCT/IL02/00199, filed March 12, 2002,
which claims priority from U.S. Patent application No. 09/802,928, filed March
12, 2001, now U.S. Patent No. 6,562,319, issued May 13, 2003.

FIELD AND BACKGROUND OF THE INVENTION

The present invention relates to radiolabeled compounds and their use in
radioimaging and/or radiotherapy. More particularly, the present invention
relates to radiolabeled irreversible inhibitors of epidermal growth factor
receptor tyrosine kinase (EGFR-TK) and their use as biomarkers for medicinal
radioimaging such as Positron Emission Tomography (PET) and Single Photon
Emission Computed Tomography (SPECT), and as radiopharmaceuticals for
radiotherapy.

The use of radioactive nuclides for medicinal purposes is well known in
the art. Biologically active compounds that bind to specific cell surface
receptors or that in other ways modify cellular functions have received some
consideration as radiopharmaceuticals, and therefore, when labeled with a
radioactive nuclide, such compounds are used as biospecific agents in
radioimaging and radiotherapy.

Positron Emission Tomography (PET), a nuclear medicine imaging
technology which allows the three-dimensional, quantitative determination of
the distribution of radioactivity within the human body, is becoming an
increasingly important tool for the measurement of physiological, biochemical,